What is Turning Point Brands's latest dividend and current dividend yield?

What were the key takeaways from Turning Point Brands's earnings call?

Did Turning Point Brands beat or miss consensus estimates last quarter?

What does Turning Point Brands do and what are its main business segments?

What factors drove the changes in Turning Point Brands's revenue and profit?

What were the key takeaways from Turning Point Brands’s earnings call?

What is Turning Point Brands's gross profit margin?

What guidance did Turning Point Brands's management provide for the next earnings period?

- **Revenue Growth**: Q4 2025 revenue up 29% YoY to $121M, driven by Modern Oral ($41.3M, +266% YoY). 
- **Margin Expansion**: 2026 gross margin expected to improve with domestic production ramp. 
- **Strategic Investments**: $4-5M annualized in Modern Oral sales/marketing; Louisville factory to qualify Q1 2026. 
- **ALP Launch**: Bricks-and-mortar rollout Q2 2026, targeting 5-6 widely distributed nicotine pouch brands. 
- **Tax Resilience**: Industry-wide tax impacts seen as neutral competitive factor.

**【CEO Summary Section】**
- Q4 2025 revenue reached $121 million (+29% YoY), with Modern Oral net revenue at $41.3 million (+266% YoY). Adjusted EBITDA was $30 million (+14% YoY). 
- 2026 guidance: Modern Oral gross sales $220-$240M, net sales $180-$190M. Q1 2026 EBITDA expected $24-$27M. 
- White pouch brands (FRE/ALP) now account for 34% of total net sales. ALP to launch in bricks-and-mortar Q2 2026, ahead of original D2C-only plan. 
- Long-term target: double-digit market share in nicotine pouch category. 

**【CFO Financial Commentary】**
- Q4 2025 gross margin 55.9% (flat YoY). SG&A $47.7M (+$3.1M sequentially) due to Modern Oral investments. 
- Free cash flow $19.2M. 2026 CapEx: $4-5M (excluding Modern Oral PMTA costs). 
- 2026 tax rate 23%-26%. 

**【CRO Go-To-Market Strategy】**
- Doubling sales force ahead of schedule. New sales tools driving retail assortment and shelf space. 
- ALP bricks-and-mortar expansion to begin Q2 2026. FRE distribution expanding in c-stores and national chains. 
- Stoker's Proud launched to attract value-conscious consumers. 

**【Q&A Highlights】**
- Q1 2026 EBITDA guidance reflects upfront investments in ALP launch and sales/marketing. 
- Domestic production lines in Louisville expected to qualify Q1 2026. U.S. manufacturing to supplement Indian partner capacity. 
- Tax hikes on nicotine pouches seen as industry-wide, not competitive disadvantage. 
- Innovation focus on existing flavor profiles; no immediate plans for new flavors. 
- Store count growth for FRE/ALP expected to remain robust, with emphasis on share of shelf in existing accounts.

Turning Point Brands, Inc. (TPB) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: 31% YoY to $119M, with modern oral up 628% YoY.
- **Margin Expansion**: Gross margin +360bps to 59.2%, EBITDA margin 26.3%.
- **Strategic Investments**: $100M raised for salesforce (ahead of 2026 target), U.S. manufacturing, and international expansion.
- **Category Outlook**: Bullish on $10B+ modern oral market, with 5-6 dominant brands; Fre/On! positioned for double-digit share.
- **Risks**: Tariffs, promotional competition, and supply chain execution.

**【CEO Opening Remarks】**
- Expressed condolences for the UPS flight tragedy, emphasizing community ties without direct employee impact.
- Q3 revenue surged 31% YoY to $119M, driven by modern oral products (628% YoY growth in white pouches).
- Raised 2025 EBITDA guidance to $115-$120M (from $110-$114M) and modern oral sales to $125-$130M (from $100-$110M).
- Highlighted strategic investments: $100M raised via ATM for salesforce expansion, manufacturing, and international growth.
- Modern oral brands Fre and On! outperformed, with Fre launching new SKUs and On! entering brick-and-mortar.

**【CFO Financial Commentary】**
- Gross margin improved 360bps YoY to 59.2%, driven by modern oral scale and cost efficiencies.
- Adjusted EBITDA rose 17% YoY to $31.3M, with 26.3% margin.
- Cash balance of $201M, with $97.5M net proceeds from ATM to fund white pouch expansion.
- 2026 U.S. manufacturing lines expected to reduce tariffs and freight costs.

**【Q&A Highlights】**
- **Distribution & Market Share**: Fre and On! gaining shelf space, with On! entering brick-and-mortar. Management cautious on in-store share but optimistic on long-term growth.
- **Promotional Environment**: Competitors' promotions seen as category growth drivers; company maintains pricing integrity, focusing on brand building.
- **Profitability Balance**: 26% EBITDA margin maintained despite investments; expect measured spending on high ROI initiatives.
- **Manufacturing Costs**: Onshore production expected to reduce COGS by $0.02-$0.03/unit, offsetting tariffs.
- **Stoker Segment**: MST and loose leaf growth driven by share gains and pricing, despite category headwinds.
- **Loyalty Programs**: Fre and On! subscription growth seen as key retention metric, with first-party data insights.


Turning Point Brands, Inc. (TPB) Q3 2025 Earnings Call Transcript

- **Revenue Surge**: 25% YoY growth to $116.6 million, driven by Modern Oral ($30.1M, 26% of total) and 8x YoY white pouch sales.
- **Profit Expansion**: EBITDA up 15% to $30.5M, with full-year guidance raised to $110-$114M. Modern Oral sales target increased to $100-$110M.
- **Strategic Momentum**: Doubling sales force by 2026, ALP entering retail ahead of schedule, and U.S. manufacturing investments to offset tariffs.
- **Category Leadership**: Aiming for double-digit share in $10B+ nicotine pouch market, with 5-6 dominant brands expected.
- **Operational Resilience**: 63% YoY growth in Stoker's segment, despite cigar category headwinds, and strong cash flow generation.

**【CEO Summary Section】**
- **Revenue Growth**: Q2 revenue increased 25% YoY to $116.6 million, with Modern Oral contributing $30.1 million (26% of total revenue). White pouch sales grew nearly 8x YoY and 35% sequentially.
- **EBITDA Expansion**: Adjusted EBITDA rose 15% YoY to $30.5 million, with updated full-year guidance of $110-$114 million (up from $108-$113 million).
- **Strategic Investments**: Doubling the 2024 sales force by 2026, prioritizing white pouch distribution, and U.S. manufacturing expansion. ALP is now a top D2C pouch brand, with brick-and-mortar rollout ahead of schedule.
- **Category Outlook**: Targeting double-digit market share in the $10 billion+ nicotine pouch category by end of decade, with 5-6 dominant brands.

**【CFO Financial Commentary】**
- **Gross Margin Improvement**: 57.1% gross margin (+310bps YoY), driven by Modern Oral mix. Stoker's MST share rose 60bps to 11.8%, with chewing tobacco at 32.7% market share.
- **Cost Management**: SG&A up $3.9 million sequentially due to sales/marketing and freight costs. Free cash flow was $11.2 million, with $109.1 million in cash.
- **Guidance Updates**: Full-year Modern Oral sales raised to $100-$110 million (from $80-$95 million). CapEx for 2025 is $4-$5 million, plus $3-$5 million for PMTA-related expenses.
- **Tariff Mitigation**: Building inventory buffers, negotiating supplier discounts, and U.S. production investments to offset tariffs.

**【CRO Go-to-Market Initiatives】**
- **Sales Force Expansion**: Doubling 2024 headcount by 2026, with early success in chain partnerships and distribution growth.
- **Marketing Partnerships**: PBR sponsorship to enhance FRE's authenticity and consumer engagement. New Zig-Zag products (hemp cones, pop tubes) show early traction.
- **Brick-and-Mortar Rollout**: ALP entering retail sooner than expected, with FRE targeting ubiquity. Slotting fees and promotional investments reflect competitive market dynamics.

**【Q&A Highlights】**
- **ALP Distribution**: Early brick-and-mortar progress, with potential overlap with FRE in stores. National chain conversations advancing.
- **Tariff Strategy**: Inventory insulation, supplier cost reductions, and U.S. manufacturing investments to manage headwinds.
- **Gross Margin Dynamics**: Modern Oral mix driving margin expansion, despite D2C/brick-and-mortar channel variability. Long-term bullish on white pouch margins.
- **Sales Incentives**: Aggressive hiring and training to accelerate distribution, with focus on new talent acquisition.
- **Promotional Environment**: Competitor promotions building category awareness, with TPB maintaining premium positioning through product differentiation.


Turning Point Brands, Inc. (TPB) Q2 2025 Earnings Call Transcript

- **Revenue Supercharge**: 28% YoY growth to $106.4M, driven by modern oral sales tripling to $22.3M.
- **Guidance Upgrade**: Modern oral sales target raised to $80-$95M, reflecting 10x YoY white pouch growth.
- **Margin Focus**: 56% gross margin despite mix shift; $12.4M free cash flow supports strategic investments.
- **Tariff Headwind**: $5-7M tariff impact on imported products; exploring U.S. manufacturing for white pouches.
- **Long-Term Vision**: Aiming for double-digit share in $5+ billion white pouch market by decade end.

**【CEO Summary Section】**
- Q1 2025 revenue increased 28% YoY to $106.4 million, driven by modern oral nicotine pouch sales of $22.3 million.
- Adjusted EBITDA rose 12% YoY to $27.7 million, with full-year guidance reaffirmed at $108-$113 million.
- Modern oral sales guidance raised to $80-$95 million (from $60-$80 million), reflecting white pouch growth and $5-7 million tariff impact.
- White nicotine pouch sales surged 10x YoY, with ALP launch contributing to sequential 2x growth.
- Long-term target: double-digit market share in the $5+ billion white pouch category by end of decade.

**【CFO Financial Commentary】**
- Gross margin 56% (down 220bps YoY, flat QoQ) due to mix shift toward lower-margin modern oral products.
- SG&A increased $1.8 million QoQ to $36.4 million, driven by ALP launch and freight costs.
- Free cash flow $12.4 million; CapEx $2.2 million, with $3-5 million allocated to modern oral PMTA.
- Cash balance $99.6 million; no payments for Q1 tobacco leaf purchases yet.

**【CMO Market Initiatives】**
- Expanded sales force to enhance store visits, distribution, and inventory management.
- Strategic marketing: billboards on I-95, 7-Eleven trial, and Times Square takeover for Zig-Zag hemp cones.
- Shifting resources to white pouches, including potential U.S. manufacturing to improve margins and mitigate supply chain risk.

**【Q&A Key Takeaways】**
- ALP distribution focuses on online DTC and ALP's existing marketing channels; FRE prioritizes brick-and-mortar expansion.
- Current MST facilities can handle pouch production, but onshoring exploration underway.
- Tariffs (10% assumed rate) and FX headwinds in Zig-Zag segment impacting guidance.
- PMTA approval timing uncertain due to FDA headcount reductions; no changes to regulatory strategy.
- White pouch margins align with prior guidance; long-term focus on scale over short-term profitability.

Turning Point Brands (TPB)-7 May 25-2025 Q1 Earnings call transcript

- **Record 2024 Performance**: $104.5M Adjusted EBITDA vs. prior guidance of $101-$103M, driven by 13% Q4 revenue growth.
- **Modern Oral Growth Engine**: $60-$80M 2025 target for FRE & ALP, with FRE sales quadrupling year-over-year.
- **Zig-Zag Expansion**: 4% growth (excluding Clipper) in Q4, targeting 10% market share of smoking accessories.
- **FDA Regulatory Clarity**: ZYN’s flavored product approval signals agency openness to harm reduction innovation.
- **Financial Strength**: $56.3M free cash flow in 2024; $300M debt refinanced to 2032 maturity with 2.0-3.0x leverage ratio.


**【CEO Summary Section】**
- Q4 2024 revenue increased 13% to $93.7 million, with full-year Adjusted EBITDA up 12% to $104.5 million.
- 2025 guidance: Adjusted EBITDA of $108-$113 million, driven by $60-$80 million in Modern Oral (FRE & ALP) revenue.
- Zig-Zag growth initiatives include 4% revenue growth (excluding Clipper) and expansion into cannabis-friendly states.
- Stoker’s MST share rose 50bps to 7.6%, with Modern Oral sales quadrupling year-over-year.

**【CFO Financial Commentary】**
- Full-year gross margin declined 39bps to 55.9%, driven by product mix.
- 2025 CapEx: $4-$5 million (excluding $3-$6 million for FDA PMTA support).
- Free cash flow for 2024: $56.3 million; $300M debt refinanced to 2032 maturity.

**【CMO Market Updates】**
- FRE sales grew 26% sequentially, with 6mg pouches expanding to retail.
- ALP launch in Q4 generated strong early traction via joint venture with Tucker Carlson Network.
- Zig-Zag expanding into 7,000+ hemp retail outlets, leveraging cross-selling with Modern Oral.

**【Q&A Highlights】**
- Modern Oral distribution: 70%+ of category sold through convenience chains; 7-Eleven regional rollout shows promise.
- FDA nicotine cap: ZYN’s flavored product approval viewed as positive regulatory signal.
- Manufacturing strategy: Considering U.S. production for Modern Oral to mitigate supply chain risks.
- Contribution margin: Modern Oral gross margins ~35%, with reinvestments in sales & marketing.


Actual												0.51	0.47	0.4	0.65	0.57	0.73	0.65	0.57	0.55	0.3	0.6	-0.93	0.41	0.53	0.58	0.53	0.63	0.68	0.68	0.13	0.79	0.79	1.13	0.42
Forecast												0.375	0.45	0.3175	0.59	0.5833	0.5533	0.57	0.41	0.5	0.5767	0.49	0.385	0.4567	0.5	0.53	0.595	0.565	0.635	0.6867	0.675	0.6975	0.734	0.748	0.87
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+36.00%	+4.44%	+25.98%	+10.17%	-2.28%	+31.94%	+14.04%	+39.02%	+10.00%	-47.98%	+22.45%	-341.56%	-10.23%	+6.00%	+9.43%	-10.92%	+11.50%	+7.09%	-0.98%	-80.74%	+13.26%	+7.63%	+51.07%	-51.72%

TPB

TPB fundamentals

TPB Q4 2025 Earnings

Earnings Call

You can ask Aime

TPB

TPB fundamentals

TPB Q4 2025 Earnings

Earnings Call

TPB Earnings Call Summary for Q4/20259:00 AM on Mar 2, 2026

TPB Earnings Call Summary for Q3/20258:30 AM on Nov 5, 2025

TPB Earnings Call Summary for Q2/20259:30 AM on Aug 6, 2025

TPB Earnings Call Summary for Q1/20259:30 AM on May 7, 2025

TPB Earnings Call Summary for Q4/202410:00 AM on Mar 6, 2025

You can ask Aime